Ma Ai Thanda Han

Dr. Ma Ai Thanda Han

Rutgers NJMS
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
CKChristopher Koh
Christopher Koh
LCLaetitia Canini
Laetitia Canini
HDHarel Dahari
Harel Dahari
XZXiongce Zhao
Xiongce Zhao
SUSusan L Uprichard
Susan L Uprichard
THTheo Heller
Theo Heller

1 March 2019 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
MHMa Ai Thanda Han
Ma Ai Thanda Han
OAOsama Altayar
Osama Altayar
SHShadi Hamdeh
Shadi Hamdeh
VTVarun Takyar
Varun Takyar
YRYaron Rotman
Yaron Rotman
MNMazen Noureddin
Mazen Noureddin

11 July 2020 in Liver International
Verified
Journal Article
Closed access
PDF file
MHMa Ai Thanda Han
Ma Ai Thanda Han
AVAarshi Vipani
Aarshi Vipani
NNNabil Noureddin
Nabil Noureddin
KRKim Ramirez
Kim Ramirez
JGJeffrey Gornbein
Jeffrey Gornbein
MNMazen Noureddin
Mazen Noureddin

1 January 2017 in BioMed Research International
Verified
Journal Article
Open access
PDF file
AGAhmed M Gharib
Ahmed M Gharib
MHMa Ai Thanda Han
Ma Ai Thanda Han
EMEric Meissner
Eric Meissner
DKDavid E. Kleiner
David E. Kleiner
XZXiongce Zhao
Xiongce Zhao
CMCaryn G. Morse
Caryn G. Morse
Background.Portal hypertension, an elevation in the hepatic venous pressure gradient (HVPG), can be used to monitor disease progression and response to therapy in cirrhosis. Since obtaining HVPG measurements is invasive, reliable noninvasive methods of assessing portal hypertension are needed.Methods.Noninvasive markers of fibrosis, including magnetic resonance elastography (MRE) shear wave velocity, were correlated with histologic fibrosis and HVPG measurements in hepatitis C (HCV) and/or HIV-infected patients with advanced liver disease enrolled in a clinical trial of treatment with simtuzumab, an anti-LOXL2 antibody.Results.This exploratory analysis includes 23 subjects: 9 with HCV monoinfection, 9 with HIV and HCV, and 5 with HIV and nonalcoholic steatohepatitis. Median Ishak fibrosis score was 4 (range 1–6); 11 subjects (48%) had cirrhosis. Median HVPG was 6 mmHg (range 3–16). Liver stiffness measured by MRE correlated with HVPG (r=0.64,p=0.01), histologic fibrosis score (r=0.71,p=0.004), noninvasive fibrosis indices, including APRI (r=0.81,p<0.001), and soluble LOXL2 (r=0.82,p=0.001). On stepwise multivariate regression analysis, MRE was the only variable independently associated with HVPG (R2=0.377,p=0.02).Conclusions.MRE of the liver correlated independently with HVPG. MRE is a valid noninvasive measure of liver disease severity and may prove to be a useful tool for noninvasive portal hypertension assessment.Trial Registration Number. This trial is registered withNCT01707472.

9 March 2017 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
MHMa Ai Thanda Han
Ma Ai Thanda Han
RSRola Saouaf
Rola Saouaf
WAWalid Ayoub
Walid Ayoub
TTTsuyoshi Todo
Tsuyoshi Todo
EMEdward Mena
Edward Mena
MNMazen Noureddin
Mazen Noureddin
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and cirrhosis worldwide and the second most common cause of liver transplantation in major medical centers. Because liver steatosis and fibrosis severity are related to disease morbidity and mortality, the extent of disease, and disease progression, they need to be assessed and monitored. In addition, innovation with new drug developments requires disease staging and monitoring in both phase 2 and 3 clinical trials. Currently, disease assessment in both clinical practice and research is mostly performed by liver biopsy, an invasive, procedure with risks. Noninvasive, highly accurate tests are needed that could be used in clinical trials as surrogate endpoints and in clinical practice for monitoring patients. Area Covered: We discuss noninvasive tests, transient elastography (TE) with controlled attenuation parameter (CAP), magnetic resonance imaging (MRI), and MR elastography (MRE), summarize the available evidence of their usefulness for assessing steatosis and fibrosis. Therefore they could be used as clinical trials outcomes and in disease monitoring in clinical practice. Expert Commentary: TE with CAP, MRI and MRE are highly accurate noninvasive diagnostic tools for quantifying hepatic steatosis and fibrosis. Therefore they could be used as clinical trials outcomes and in disease monitoring in clinical practice.

14 December 2020 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
PDF file
MHMa Ai Thanda Han
Ma Ai Thanda Han
QYQi Yu
Qi Yu
ZTZaid Tafesh
Zaid Tafesh
NPNikolaos Pyrsopoulos
Nikolaos Pyrsopoulos
Globally, the rise in prevalence of obesity and metabolic syndrome as a whole has been linked to increased access to processed foods, such as refined sugars and saturated fats. Consequently, nonalcoholic fatty liver disease (NAFLD) is on the rise in both developed and developing nations. However, much is still unknown on the NAFLD phenotype with regards to the effect of ethnic diversity. Despite similarities in dietary habits, it appears that certain ethnicities are more protected against NAFLD than others. However, manifestations of the same genetic polymorphisms in different groups of people increase those individuals’ predisposition to NAFLD. Diets from different regions have been associated with a lower prevalence of NAFLD and have even been linked to regression of hepatic steatosis. Socioeconomic variations amongst different regions of the world also contribute to NAFLD prevalence and associated complications. Thus, a thorough understanding of ethnic variability in NAFLD is essential to tailoring treatment recommendations to patients of different backgrounds.